Literature DB >> 27568543

Biochemical validity of imaging techniques (X-ray, MRI, and dGEMRIC) in degenerative disc disease of the human cervical spine-an in vivo study.

Richard Bostelmann1, Tamara Bostelmann2, Adrian Nasaca2, Hans Jakob Steiger2, Frank Zaucke3, Christoph Schleich4.   

Abstract

BACKGROUND CONTEXT: On a molecular level, maturation or degeneration of human intervertebral disc is among others expressed by the content of glycosaminoglycans (GAGs). According to the degenerative status, the disc content can differ in nucleus pulposus (NP) and annulus fibrosus (AF), respectively. Research in this area was conducted mostly on postmortem samples. Although several radiological classification systems exist, none includes biochemical features. Therefore, we focused our in vivo study on a widely spread and less expensive imaging technique for the cervical spine and the correlation of radiological patterns to biochemical equivalents in the intervertebral discs.
PURPOSE: The aim of this pilot study was to (1) measure the GAG content in human cervical discs, (2) to investigate whether a topographic biochemical GAG pattern can be found, and (3) whether there is a correlation between imaging data (X-ray and magnetic resonance imaging [MRI] including delayed gadolinium-enhanced MRI of cartilage [dGEMRIC] as a special imaging technique of cartilage) and the biochemical data. STUDY DESIGN/SAMPLE: We conducted a prospective experimental pilot study. PATIENT SAMPLE: Only non-responders to conservative therapy were included. All subjects were physically and neurologically examined, and they completed their questionnaires. OUTCOME MEASURES: Visual analogue scale neck and arm, Neck Disability Index score, radiological parameters (X-rays, MRI, dGEMRIC), and the content of GAG in the cervical disc were assessed.
METHODS: After surgical removal of 12 discs, 96 fractions of AF and NP were biochemically analyzed for the GAG content using dimethylmethylene blue assay.
RESULTS: A quantitative pattern of GAGs in the human cervical disc was identified. There were (1) significantly (p<.001) higher values of GAGs (µg GAG/mg tissue) in the NP (169.9 SD 37.3) compared with the AF (132.4 SD 42.2), and (2) significantly (p<.005) higher values of GAGs in the posterior (right/left: 149.9/160.2) compared with the anterior (right/left: 112.0/120.2) part of the AF. Third, we found in dGEMRIC imaging a significantly (p<.008) different distribution of GAGs in the cervical disc (NP 1083.3 ms [SD 248.6], AF 925.9 ms [SD 137.6]). Finally, we found that grading of disc degeneration in X-ray and MRI was significantly correlated with neither AF- nor NP-GAG content.
CONCLUSIONS: The GAG content in human cervical discs can be detected in vivo and is subject to a significantly (p<.05) region-specific pattern (AF vs. NP; anterior vs. posterior in the AF). Up to the levels of AF and NP, this is reproducible in MRI in dGEMRIC technique, but not in X-ray or standard MRI sequences. Potentially, the MRI in dGEMRIC technique can be used as a non-invasive in vivo indicator for disc degeneration in the cervical spine.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biochemistry of the disc; Cervical spine; Disc degeneration; Discopathy; GAG; Image processing; dGEMRIC

Mesh:

Substances:

Year:  2016        PMID: 27568543     DOI: 10.1016/j.spinee.2016.08.031

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  2 in total

1.  A Histopathological Scheme for the Quantitative Scoring of Intervertebral Disc Degeneration and the Therapeutic Utility of Adult Mesenchymal Stem Cells for Intervertebral Disc Regeneration.

Authors:  Cindy C Shu; Margaret M Smith; Susan M Smith; Andrew J Dart; Christopher B Little; James Melrose
Journal:  Int J Mol Sci       Date:  2017-05-12       Impact factor: 5.923

2.  An MRI study of solute transport in the intervertebral disc.

Authors:  Rachel M Palfrey; Ian R Summers; C Peter Winlove
Journal:  MAGMA       Date:  2019-10-04       Impact factor: 2.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.